These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 28032956)
1. Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients. Contis A; Gensous N; Viallard JF; Goizet C; Léauté-Labrèze C; Duffau P Clin Otolaryngol; 2017 Aug; 42(4):911-917. PubMed ID: 28032956 [No Abstract] [Full Text] [Related]
2. Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report. Mei-Zahav M; Blau H; Bruckheimer E; Zur E; Goldschmidt N J Otolaryngol Head Neck Surg; 2017 Oct; 46(1):58. PubMed ID: 28978360 [TBL] [Abstract][Full Text] [Related]
3. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Olitsky SE Am J Otolaryngol; 2012; 33(3):375-6. PubMed ID: 22079094 [No Abstract] [Full Text] [Related]
4. Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Dupuis-Girod S; Pitiot V; Bergerot C; Fargeton AE; Beaudoin M; Decullier E; Bréant V; Colombet B; Philouze P; Faure F; Letievant JC Sci Rep; 2019 Aug; 9(1):11986. PubMed ID: 31427745 [TBL] [Abstract][Full Text] [Related]
5. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. Harrison L; Kundra A; Jervis P J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780 [TBL] [Abstract][Full Text] [Related]
6. The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review. Albarki H; Rimmer J Am J Rhinol Allergy; 2022 Nov; 36(6):890-896. PubMed ID: 35929049 [TBL] [Abstract][Full Text] [Related]
7. Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia. Ichimura K; Kikuchi H; Imayoshi S; Dias MS Auris Nasus Larynx; 2016 Aug; 43(4):429-32. PubMed ID: 26739947 [TBL] [Abstract][Full Text] [Related]
8. Coblation for epistaxis management in patients with hereditary haemorrhagic telangiectasia: a multicentre case series. Joshi H; Woodworth BA; Carney AS J Laryngol Otol; 2011 Nov; 125(11):1176-80. PubMed ID: 21846415 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Invernizzi R; Quaglia F; Klersy C; Pagella F; Ornati F; Chu F; Matti E; Spinozzi G; Plumitallo S; Grignani P; Olivieri C; Bastia R; Bellistri F; Danesino C; Benazzo M; Balduini CL Lancet Haematol; 2015 Nov; 2(11):e465-73. PubMed ID: 26686256 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Sabbà C; Gallitelli M; Palasciano G N Engl J Med; 2001 Sep; 345(12):926. PubMed ID: 11565536 [No Abstract] [Full Text] [Related]
12. A retrospective study of the role of the argon laser in the management of epistaxis secondary to hereditary haemorrhagic telangiectasia. Lennox PA; Harries M; Lund VJ; Howard DJ J Laryngol Otol; 1997 Jan; 111(1):34-7. PubMed ID: 9292128 [TBL] [Abstract][Full Text] [Related]
14. Domiciliary floseal prevents admission for epistaxis in hereditary hemorrhagic telangiectasia. Warner L; Halliday J; James K; de Carpentier J Laryngoscope; 2014 Oct; 124(10):2238-40. PubMed ID: 24706356 [No Abstract] [Full Text] [Related]
15. Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia. Minami K; Haji T Acta Otolaryngol; 2016; 136(5):528-31. PubMed ID: 26808464 [TBL] [Abstract][Full Text] [Related]
16. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab. Alderman C; Corlett J; Cullis J Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440 [No Abstract] [Full Text] [Related]
17. [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid]. Morales-Angulo C; Pérez del Molino A; Zarrabeitia R; Fernández A; Sanz-Rodríguez F; Botella LM Acta Otorrinolaringol Esp; 2007 Apr; 58(4):129-32. PubMed ID: 17428407 [TBL] [Abstract][Full Text] [Related]
18. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282 [TBL] [Abstract][Full Text] [Related]